CD19 chimeric antigen receptor T (CAR-T) cells demonstrate remarkable remission rates in pediatric and adult patients with refractory or relapsed (r/r) acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). In 2016, the authors initiated a clinical trial with in-house produced CD19...
Recently, the use of immune checkpoint inhibitors has gained attention in the treatment of both cutaneous squamous cell carcinoma and hematological malignancies. However, many patients with hematological malignancies eventually undergo allo-HCT, raising the concern of potential adverse events ...
Hepatitis B virus (HBV) reactivation is commonly seen in HBsAg-positive hematologic patients undergoing immunosuppressive chemotherapy. Little is known about the risk of HBV reactivation after chimeric antigen receptor T-cell (CAR T) immunotherapy for the treatment of refractory/relapsed...
Despite chemo-induction therapy and autologous stem cell transplantation (ASCT), the vast majority of patients with Multiple Myeloma (MM) relapse within 7 years and the disease remains incurable. Adoptive Allogeneic T-cell therapy (ATCT) might be curative for MM, however current ATCT protocols...
Diffuse large B-cell lymphoma (DLBCL) harbors somatic hypermutation (SHM) in the immunoglobulin heavy chain and light chain variable region genes, IGHV and IGK/LV. Recent studies have revealed that IGV SHM creates neoantigens that activate T-cell responses against B-cell lymphoma. The authors...
Presentation slides and video from the 2019 Advances in Cancer Immunotherapy TM - San Diego, CA, held on December 12, 2019 are available here. Program Organizers Christopher Coyne, MD, MPH – University of California San Diego Sandip P. Patel, MD – University of California San...
19 attachments
From the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) post-program webinar recording for the Charleston event is provided here. The purpose of...
Advances in Cancer Immunotherapy™ Post-Program Webinar 2 (Charleston).mp4
Samalizumab is a novel recombinant humanized monoclonal antibody that targets CD200, an immunoregulatory cell surface member of the immunoglobulin superfamily that dampens excessive immune responses and maintains self-tolerance. This first-in-human study investigated the therapeutic use of...
Voices of Immunotherapy is a video library presented by Cancer Support Community (CSC). Here, patients and healthcare professionals discuss their experiences with immunotherapy. Click here to browse the entire video library or click on a link below for the specific video: Immunotherapy...
Presentation slides and video from the 2019 Advances in Cancer Immunotherapy TM - Nashville, TN, held on December 4, 2019 are available here. **Note: Due to technical difficulties, Dr. Melissa L. Johnson’s "Toxicity Management" presentation was not fully recorded. A video of the Toxicity...
21 attachments
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us